Cangrelor Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 50 mg
Reference Brands: Kengreal (USA/EU)
Category:
Heart Disorder
Cangrelor is available in Injection
and strengths such as 50 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Cangrelor is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Cangrelor can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Cangrelor is a potent, fast-acting intravenous antiplatelet agent approved for use in patients undergoing percutaneous coronary intervention (PCI). It is indicated to reduce the risk of thrombotic cardiovascular events in patients who have not been treated with oral P2Y12 inhibitors or who are unable to receive oral antiplatelet therapy. The clinical efficacy of cangrelor is attributed to its direct, reversible inhibition of the P2Y12 platelet receptor, resulting in rapid and consistent platelet inhibition.
Cangrelor is characterized by an immediate onset of action and a very short half-life, allowing for precise control of antiplatelet effects during and immediately after PCI. Its pharmacokinetic and pharmacodynamic profile enables quick recovery of platelet function once the infusion is discontinued, making it suitable for use in acute and procedural settings.
The drug is generally well tolerated, though healthcare professionals should remain aware of potential adverse drug reactions, contraindications, and drug interactions associated with antiplatelet therapy. Proper patient selection, dosing, and monitoring are essential to optimize clinical outcomes. Effective interprofessional collaboration among cardiologists, pharmacists, and nursing staff plays a critical role in ensuring the safe and effective use of cangrelor in cardiovascular care.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing